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Summary
Purpose: The main objective of our study was to determine which combination of 
modifiable	and	non-modifiable	parameters	that	could	discriminate	patients	with	noc-
turia	from	those	without	nocturia.	This	was	a	post-hoc	analysis	of	3	prospective,	ob-
servational	studies	conducted	in	Ghent	University.	Participants	completed	frequency	
volume chart (FVC) to compare characteristics between patients with and without 
nocturia.
Method: This	was	 a	 post	 hoc	 analysis	 of	 three	 prospective,	 observational	 studies	
conducted	 in	 Ghent	 University.	 Participants	 completed	 frequency	 volume	 chart	
(FVC) to compare characteristics between adults with and without nocturia.
Study 1: adults with and without nocturia (n = 148);
Study	2:	patients	≥65	years	with	and	without	nocturnal	LUTS	(n	=	54);
Study 3: menopausal women before and after hormone replacement therapy (n = 43).
All	 eligible	 patients	 (n	=	183)	 completed	 a	 FVC	 during	 24	hours	 (n	=	13),	 48	hours	
(n = 30) or 72 hours (n = 140). The combination of algorithms and number of determi-
nants	obtaining	the	best	average	area	under	the	receiver	operating	curve	(AUC-ROC)	
led	to	the	final	model.	Differences	between	groups	were	assessed	using	the	AUC-ROC	
and	Mann-	Whitney-Wilcoxon	tests.	Holm	corrections	were	applied	for	multiple	sta-
tistical	testing.	Also,	the	stability	of	the	feature	selection	was	evaluated.
Results: The best discrimination was obtained when 13 determinants were included. 
However,	a	logistic	regression	model	based	on	seven	determinants	selected	with	ran-
dom	forest	had	comparable	discrimination	including	an	optimal	signature	stability.	It	
was able to discriminate almost perfectly between nights with and without 
nocturia.
Conclusion: Relevant	 information	 to	accomplish	 the	excellent	predictability	of	 the	
model	is;	functional	bladder	capacity,	24	hours	urine	output,	nocturnal	output,	age,	
BMI.	The	multivariate	model	used	in	this	analysis	provides	new	insights	into	combina-
tion therapy as it allows simulating the effect of different available treatment modali-
ties and its combinations.
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1  | INTRODUC TION
Nocturia,	or	waking	at	night	at	least	once	to	void,	is	a	common	and	
bothersome	lower	urinary	tract	symptom	(LUTS)	that	results	from	
an imbalance between functional bladder storage capacity and 
urine production.1	 Inadequate	 functional	bladder	 storage	 results	
in small voided volumes and can be caused by different underlying 
conditions,	such	as	urinary	tract	infections,	idiopathic/neurogenic	
detrusor	 over	 activity,	 and	 bladder	 outlet	 obstruction	 because	
of	benign	prostate	enlargement	 (BPE).	 Increased	urinary	output,	
which	can	be	overnight	only	or	during	a	24-hour	period,	can	also	
develop	 for	 a	 variety	 of	 reasons	 such	 as	 heart	 failure,	 diabetes	
insipidus	or	mellitus,	decreased	vasopressin	 levels,	venous	 insuf-
ficiency	or	obstructive	sleep	apnoea.	In	order	to	initiate	appropri-
ate	 treatment,	 a	 frequency	 volume	 chart	 (FVC)	 is	 recommended	
as an indispensable tool to subtype nocturia patients according 
to the underlying aetiology: reduced functional bladder capac-
ity	(FBC),	24	hours	polyuria,	nocturnal	polyuria	(NP)	or	combined	
aetiology.2	Treatments	to	improve	FBC	include	anticholinergics	in	
patients with detrusor over activity and symptoms of overactive 
bladder	 (OAB),	 whereas	 recently	 introduced	 treatment	 for	 OAB	
–	 beta-3-agonist	 –	 stimulates	 beta-3	 receptors,	 causing	 smooth	
muscle	 relaxation	 in	 the	bladder	and	α-blockers	or	5α-reductase	
inhibitors	in	the	case	of	BPE.	Therapeutic	measures	directed	to	re-
duce	nocturnal	urinary	output	include	evening	fluid	restriction,	leg	
elevation	 during	 daytime,	 timed	 diuretics	 and	 antidiuretic	 treat-
ment with desmopressin.3,4	Despite	this	knowledge,	management	
of nocturia patients remains to be challenging because unambigu-
ous	definitions	of	NP	and	 reduced	FBC	are	 lacking,	 and	 there	 is	
little evidence with reference to the effect of all possible combi-
nations of treatment modalities in case of a combined aetiology of 
nocturia.2,3,5,6
Therefore,	the	aim	of	this	study	was	to	determine	which	combi-
nation of parameters derived from FVCs could discriminate patients 
with	nocturia	from	those	without	nocturia,	in	addition	to	determin-
ing the modifiable factors to minimise nocturia. This will allow to 
study the aetiology of nocturia and to estimate the effect of treat-
ment	 approaches	 that	 address	 FBC	or	 nocturnal	 urine	 production	
(NUP)	on	the	number	of	nocturnal	voids	without	the	need	of	uniform	
definitions	for	NP	or	a	reduced	FBC.
2  | MATERIAL S AND METHODS
2.1 | Study design and protocol
This	was	a	post	hoc	analysis	of	three	prospective,	observational	stud-
ies	conducted	in	Ghent	University	Hospital	between	October	2011	
and March 2016. Participants completed a FVC in order to compare 
FVC characteristics between adults with and without nocturia (study 
1;	 n	=	148),	 patients	 65	years	 or	 older	with	 and	without	 nocturnal	
LUTS	 (study	 2;	 n	=	54)	 and	 menopausal	 women	 before	 and	 after	
hormone replacement therapy (study 3; n = 43; unpublished data). 
In	study	2,	missing	values	were	corrected	if	it	concerned	one	voided	
volume (VV) during daytime on condition that there were at least 
four other daytime voids and that it was not the first morning void. 
In	that	case,	an	average	of	the	other	daytime	voids	was	calculated	for	
the missing value. The procedure was implemented as a FVC review 
session	by	the	nurse	with	an	unsolicited	question.	Incomplete	FVCs	
were	excluded	in	study	1	and	3.	Study	1	and	3	did	not	have	the	same	
review	process	as	study	2.	All	subjects	with	nocturnal	urinary	incon-
tinence	were	excluded	from	the	current	study	(n	=	34).
All	participants	eligible	 for	analyses	 (n	=	183/245)	completed	a	
FVC	during	24	hours	(n	=	13),	48	hours	(n	=	30)	or	72	hours	(n	=	140).	
Therefore,	they	registered	micturition	frequency,	volumes	and	time	
registrations of going to bed and getting up in the morning.
Ethical	approval	was	obtained	from	the	Ghent	University	Hospital	
ethics	 committee	 (EC/2011/565;	 EC/2013/950;	 EC/2014/0035;	
EC/2014/1241)	 The	 Declaration	 of	 Helsinki	 was	 followed	 and	 all	
subjects gave a written informed consent.
2.2 | Statistical analysis
2.2.1 | Determinants for nocturia
Nights	with	at	least	two	nocturnal	voids	were	considered	as	nights	
with	 nocturia,	 whereas	 nights	with	 less	 than	 two	 nocturnal	 voids	
were defined as nights without nocturia. The selection of determi-
nants was made a priori in order to include most of the determinants 
What's known
•	 It	 is	 known	 that	 the	 diagnosis	 of	 nocturnal	 polyuria	 is	
difficult.	 Applying	 the	 many	 definitions	 suggested	 to	
other populations than the original has shown low ac-
curacy.	The	ICS	definition	is	the	most	widely	evaluated	
definition and studies found sensitivity and specificity 
low,	 of	 the	 studies	 that	 have	 tested	 the	 prevalence	
found	many	of	the	non-nocturic	subject	having	noctur-
nal	 polyuria,	 which	 is	 evidence	 of	 moderate	 accuracy	
and the possibility of having a fair amount of false posi-
tive subjects.
What's new
•	 Admitting	 the	 difficulty	 in	 defining	 nocturnal	 polyuria	
the	paper	has	a	more	practical	pragmatic	approach.	By	
determining which combination of parameters derived 
from	frequency	volume	chart	that	can	discriminate	pa-
tients with nocturia from those without nocturia. This 
will allow to study the etiology of nocturia and to esti-
mate the effect of treatment approaches that address 
functional bladder capacity or nocturnal urine produc-
tion on the number of nocturnal voids without the need 
of	uniform	definitions	for	NP	or	a	reduced	FBC.
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anticipated to be relevant and in order to minimise the interdepend-
ence between determinants:
•	 general	determinants:	age	(years),	gender,	body	mass	index	(BMI;	
kg/m2)
• determinants derived from each individual night of the FVC: sleep 
duration	(hours),	24	hours	urine	output	(mL/h),	fluid	intake	during	
daytime	 (time	 between	waking	 up	 and	 6	pm),	 evening	 (time	 be-
tween 6 pm	and	going	to	sleep)	and	24	hours	(mL)	and	log	odds	of	
a	modified	NP	index:
•	 determinants	 derived	by	 taking	 the	 average	of	 all	 nights	 of	 the	
FVC:	24	hours	maximum	VV	 (mL),	 relative	24	hours	mean	urine	
output	 (=	 24	hours	 mean	 VV/24	hours	 maximum	 VV),	 relative	
nocturnal	urine	output	(=	nocturnal	mean	VV/24	hours	maximum	
VV) and log odds of nocturnal mean VV on 24 hours mean VV:
The rationale for the log odds transformation in case of ratios 
is	 justified	as	ratios	having	a	non-normal	distribution	while	the	hy-
potheses	tests	and	predictive	modelling	(see	below)	make	normality	
assumptions.
2.2.2 | Descriptive parameters
Median,	interquartile	range	and	frequency	were	recorded	as	descrip-
tive	 parameters.	 Differences	 between	 groups	 were	 assessed	 using	
the	area	under	 the	 receiver	operating	curve	 (AUC-ROC)	and	Mann-
Whitney-Wilcoxon	tests.	Holm	corrections	were	applied	for	multiple	
statistical	testing.	A	P	<	0.05	was	considered	statistically	significant.
2.2.3 | Development of a multivariate model
A	multivariate	model	of	nocturia	was	developed	by	combining:	an	al-
gorithm	for	ranking	all	possible	determinants	of	nocturia	by	decreas-
ing	relevance,	the	number	of	determinants	to	be	used	in	the	model	
and a classification algorithm modelling the presence or absence of 
nocturia	 from	 the	 selected	 determinants.	 Several	 variable	 ranking	
algorithms	were	 evaluated:	Wilcoxon	 tests,	 least	 angle	 regression	
(LARS,	 a	 linear	method)7 or random forest importance.8	 Similarly,	
several classification algorithms were evaluated: logistic regres-
sion	(LR),	random	forest,	ensemble	of	univariate	logistic	regressions	
(EULR)9	or	5-nearest-neighbours	(5NN).10 The performance of each 
combination	of	 algorithms	was	evaluated	within	 a	 cross-validation	
procedure where predictive models are repeatedly learnt (200 
times) from 80% data and tested on the remaining 20% data. This 
was applied for different numbers of descriptors.
The final model was chosen as the combination of algorithms 
and the number of determinants having the highest discrimination 
was determined by area under the curve – receiver operating curve 
(AUC-ROC).	 In	 addition,	 the	 stability	 of	 the	 feature	 selection	was	
evaluated	with	the	Kuncheva	 index,	with	a	higher	 index	 indicating	
that selection of variables was similar in all resampling loops.11
2.2.4 | Determinants of the best logistic 
regression model
Determinants	of	the	best	LR	model	are	reported	based	on	the	aver-
age	ranking,	which	is	the	average	of	the	variable	ranking	obtained	by	
the random forest feature selection over 200 resampling iterations. 
The	sign	of	the	variable's	weight	 in	an	LR	is	also	reported.	This	LR	
was	tuned	on	the	whole	dataset,	after	rescaling	variables	to	average	
zero	and	unit	standard	deviation.
3  | RESULTS
A	total	of	183	subjects,	73	(35%)	men	and	138	(65%)	women	aged	
50-67,	with	 a	median	 age	 of	 57	years	were	 enrolled	 in	 this	 study.	
Table 1 reports the descriptive parameters of all candidate deter-
minants for the total number of nights (n = 493) and compares the 
nights with (n = 180) and without (n = 313) nocturia. These descrip-
tive parameters are also detailed for each of the three datasets 
separately.	On	univariate	analysis,	6	of	the	13	considered	determi-
nants were significantly associated (P	<	0.05)	with	 nocturia	 symp-
toms:	24	hours	maximum	VV	(AUC	0.73),	log	odds	of	nocturnal	urine	
output/24	h	urine	output	 (AUC	0.70),	 relative	nocturnal	urine	out-
put	(AUC	0.63),	age	(AUC	0.63),	log	odds	of	nocturnal	mean	VV	on	
24	hours	mean	VV	(AUC	0.62)	and	gender	(AUC	0.57).
Figure	1	shows	how	the	LR	performances	were	influenced	by	
the number of determinants selected in the model. The best dis-
crimination	(AUC	of	0.98,	95%	CI	0.966-0.995)	was	obtained	when	
all	 13	 determinants	 were	 included.	 However,	 a	 logistic	 regres-
sion model based on seven determinants selected with random 
forest	had	comparable	discrimination	with	an	AUC	of	0.976	(95%	
CI	 0.961-0.991),	 had	optimal	 signature	 stability	 (Kuncheva	 index	
0.944) and was able to discriminate almost perfectly between 
nights with and without nocturia. Table 2 provides an overview 
of the best combinations of determinant selection and classifica-
tion algorithms with the corresponding performances. The linear 
weight	of	each	of	the	seven	selected	determinants	in	the	best	LR	
model is described in Table 3 with the associated P-values	of	Wald	
tests.	They	are	all	significantly	non-zero	except	for	age	and	BMI.	
Using	 Table	3,	 the	 prediction	 of	 the	 probability	 of	 experiencing	
nocturia	 according	 to	 the	 LR	model	 can	 be	 computed	 using	 the	
following formula:
log10
nocturnal urine output (mL/h)
24h urine output (mL/h)
log10
nocturnal mean VV (mL)
24hmean VV (mL)
P(nocturia|x) =
1
1+exp (−(Intercept+훽1
x1−휇1
휎1
+⋯+훽7
x7−휇7
휎7
))
=
1
1+exp (−(−3.15+6.18
x1−(−0.098)
0.28
+⋯+0.35
x7−24.7
3.9
))
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where x1 is the log odds nocturnal urine output/24 hours urine 
output,	x2	is	the	24	hours	maximum	voided	volume	(mL),	x3 is the log 
odds	nocturnal	mean	voided	volume/24	hours	mean	voided	volume,	
x4	is	the	relative	nocturnal	urine	output,	x5 is the 24 hours urine out-
put	(mL/h),	x6 is the age (years) and x7	is	the	body	mass	index	(kg/m
2) 
and the βi,	μi and σi	are	the	respective	LR	coefficients,	average	and	
standard deviations reported in Table 3.
4  | DISCUSSION
We	developed	an	explanatory	multivariate	model	that	predicts	for	
nocturia	 symptoms	 defined	 as	 two	 or	 more	 nocturnal	 voids.	 Our	
best fit logistic regression model based on 7/13 selected determi-
nants,	had	a	sensitivity	of	91%,	specificity	of	93%,	and	AUC	of	0.98	
to	 discriminate	male	 or	 female	 subjects	 aged	50-67	with	 nocturia	
F I G U R E  1  Variation	of	the	performance	of	each	model	according	to	the	number	of	selected	determinants,	with	random	forest	
importance as selection algorithm and logistic regression as classification algorithm
TA B L E  1  Univariate	analysis	of	the	determinants	of	nocturia
The	median	and	first	and	third	quartiles	of	each	variable	are	reported	for	the	overall	number	of	nights	and	for	subgroups	based	on	the	presence	of	
nocturia.	The	area	under	the	receiver-operating	curve	comparing	both	groups	is	reported,	as	well	as	the	P-value	of	a	Mann-Whitney-Wilcoxon	test	and	
the corrected P-value	after	applying	the	Holm	correction	for	multiple	statistical	testing.
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symptoms from those without nocturia. We also confirmed that an 
increased	nocturnal	urine	production	and	reduced	FBC	are	the	main	
factors that determine the presence of nocturia during a specific 
night,	while	24	hours	urine	output	and	fluid	 intake	during	daytime	
and 24 hours urine output had an inferior importance.
Limitations	of	our	study	include	the	fact	that	only	data	obtained	
from FVCs were included and that comorbidities were not recorded. 
The nocturia symptom may be because of underlying comorbidities 
such	as	diabetes	and	hypertension,	which	have	to	be	excluded	before	
the	beginning	of	LUTS	treatment.	The	length	of	recording	in	the	FVC	
also	varied	in	between	studies,	some	were	24	hours	only.	Second,	the	
age span of the included population is relative narrow and was ob-
served	to	be	a	determinant	for	the	multivariate	model,	so	it	still	needs	
to be tested in a broader age range to validate an appropriate fit.
Our	 model	 can	 contribute	 to	 new	 insights	 into	 combination	
therapy for nocturia as it allows simulating the effect of different 
available treatment modalities and their combinations. This can be 
used	to	test	several	scenarios.	For	example,	given	the	data	of	a	sin-
gle	patient,	one	could	test	if	modifying	a	given	parameter	to	some	
extent	 could	–	or	not–	modify	 its	 nocturia	 status.	The	benefit	 is	
that	the	model,	for	each	patient,	will	not	only	take	into	account	the	
modification	of	that	particular	feature,	but	will	also	bear	the	impact	
of	the	other	parameters,	left	unchanged.	A	modification	of	a	given	
parameter to some value for one patient might thus not lead to the 
same	impact	as	the	same	modification	for	another	patient,	because	
they	might	differ	in	the	other	parameters.	Also	renal	function	pro-
file	evaluation	in	NP	screening	could	discriminate	between	water	
and solute diuresis as pathophysiological mechanisms complement 
the bladder diary and could facilitate optimal individualised treat-
ment	of	patients	with	NP.	However,	 it	 is	much	more	complicated	
and	therefore	our	model	seems	to	be	a	good	easy-to-use	alterna-
tive.12	Previous	studies	have	reported	that	NP	is	the	major	cause	
of	nocturia,13 but prevalence varies widely across different studies 
because	of	the	use	of	dozens	of	different	definitions.5,6
The	most	widely	used	definition	is	based	on	the	NP	index	(NPI),	
which	is	the	ratio	of	nocturnal	urine	production	(NUP)	to	24	hours	
urine	 production.	 The	 guidelines	 issued	 by	 the	 International	
Continence	Society	(ICS)	recommends	that	the	limit	should	be	>20%	
in	younger	adults,	>33%	in	adults	65	years	and	older	and	somewhere	
in	between	 for	middle-aged	adults.	Analysis	of	FVCs	 showed	 that	
76% (641/846) of European participants and 88% (806/917) of 
American	 participants	with	 at	 least	 two	nocturia	 episodes	 had	 an	
NPI	greater	 than	33%.13	The	prevalence	of	NP	 increased	with	age	
but	was	high	in	all	age	groups	regardless	of	gender,	ethnicity,	country	
and	concomitant	therapy	for	overactive	bladder	or	BPE.	However,	
the	discriminative	value	to	diagnose	NP	as	a	cause	of	nocturia	is	lim-
ited	when	 an	NPI	 greater	 than	33%	 is	 used	 as	 a	 cut-off	 value	 for	
NP.14	In	the	Krimpen	study,	NP	was	diagnosed	in	92%	of	men	with	
nocturia	≥2,	but	also	in	70%	of	those	without	nocturia.15
The	 ICS	definition	of	NP	 is	 not	based	on	normal	 distributions,	
not thoroughly validated and not able to discriminate patients with 
nocturia	from	those	without	nocturia.	Therefore,	this	definition	has	
been challenged and other definitions have been proposed such as 
NPI	>53%,	NPI	>78%,	NUP	>90	mL/h	or	NUP	>6.4	mL/kg.5,6
TA B L E  2   Multivariate analysis of the determinants of nocturia
Selection of 
determinants
Number of 
determinants
Type of 
classification AUC (%) Sensitivity (%) Specificity (%) BCR (%) Kuncheva
Random forest 7 Logistic	regression 98	(96-99) 91	(86-97) 93	(89-98) 92	(90-95) 0.944
LARS 8 EULR 90	(85-94) 86	(77-95) 77	(69-85) 82	(77-86) 0.846
LARS 6 Random forest 93	(89-96) 69	(60-78) 93	(89-97) 81	(76-86) 0.847
BCR,	balanced	classification	rate;	EULR,	ensemble	of	univariate	logistic	regressions;	LARS,	least	angle	regression.
Performance	obtained	with	the	best	combinations	of	determinant	selection	and	classification	algorithms	in	the	resampling-based	evaluation	procedure.	
The	average	performance	measured	on	the	test	sets	is	reported	along	with	a	95%	confidence	interval.
TA B L E  3  Determinants	included	in	the	best	logistic	regression	(LR)	model
Determinants Average (μ)
Standard deviation 
(σ)
Coefficient in logistic 
regression (β) P‐valueWald test
(Intercept) — — −3.15 <0.001
Log	odds	nocturnal	urine	output/24	h	urine	
output
−0.098 0.28 6.18 <0.001
24	h	maximum	voided	volume	(mL) 485 198 −5.07 <0.001
Log	odds	nocturnal	mean	voided	vol-
ume/24 h mean voided volume
0.137 0.217 −1.00 0.012
Relative nocturnal urine output 0.653 0.211 −2.83 <0.001
24	h	urine	output	(mL/h) 89.3 45.3 5.16 <0.001
Age	(years) 55.5 15.3 −0.19 0.418
Body	mass	index	(kg/m2) 24.7 3.9 0.35 0.096
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Although	 reduced	 FBC	 is	 also	 recognised	 as	 another	 underlying	
mechanism	of	nocturia,	no	uniform	widely	accepted	definition	is	available,	
which is reflected by the various definitions used: mean voided volume 
<250	mL,	maximum	voided	volume	<300	mL).16,17 There is also evidence 
that a major proportion of nocturia patients may benefit from combina-
tion therapy to address multiple mechanisms underlying nocturia.2
Analysis	of	FVCs	obtained	from	41	men	with	two	or	more	noc-
turia	episodes	showed	that	20%	had	isolated	NP	and	63%	had	NP	in	
combination with another factor.16
FVCs obtained from 29 men and women with at least two noc-
turia	episodes	showed	an	isolated	reduced	FBC	in	7%,	isolated	NP	in	
7%,	isolated	global	polyuria	in	28%	and	the	combination	of	a	reduced	
FBC	and	NP	in	59%	of	subjects.18
Although	a	full	range	of	treatments	capable	of	meeting	the	needs	
of	patients	with	NP	or	a	reduced	FBC	are	available,	only	a	few	stud-
ies have addressed the possible combinations.
The addition of desmopressin to α-blocker	therapy	of	123	men	
with	BPE	and	nocturia	 reduced	 the	number	of	nocturnal	 voids	by	
64%,	which	was	significantly	better	that	the	45%	reduction	of	125	
men treated with α-blocker	alone.19
Administration	of	solifenacin	(5	mg	and	10	mg)	reduced	the	num-
ber	of	nocturia	episodes	in	OAB	patients	with	and	without	NP,	but	
only	 showed	 a	 significant	 reduction	 in	 patients	without	NP,	 com-
pared to placebo (P	=	0.006	for	5	mg;	P = 0.026 for 10 mg).20
5  | CONCLUSION
Based	on	a	pooled	analysis	of	 frequency	volume	charts	of	183	el-
derly	subjects,	for	both	men	and	women,	we	developed	a	multivari-
ate logistic regression model that could differentiate nights with and 
without	 nocturia.	 The	 model	 could	 achieve	 a	 Kuncheva	 index	 of	
0.944	(where	1	is	the	perfect	match),	an	AUC	of	98%,	a	sensitivity	of	
91% and specificity of 93%.
The	following	information	is	relevant	to	accomplish	the	excellent	
predictability	 of	 the	 model:	 functional	 bladder	 capacity,	 24	hours	
urine	output,	nocturnal	output,	age,	BMI.
By	 identifying	 the	 most	 important	 determinants	 for	 nocturia	
nights,	the	mixed	aetiology	of	nocturia	is	recognised.	In	addition,	the	
effect of influencing any of the parameters can lead to estimating 
the	probability	of	nocturia-free	nights	using	the	multivariate	model,	
which is of clinical benefit for the patients.
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